Sep 14, 2018, 01:00 by admin admin

This Policy Statement includes recommendations on standards related to the marketing of addiction treatment services and recruiting of patients as well as state and federal government development and dissemination of materials for consumers to detect potential fraudulent marketing and patient recruiting practices.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted a letter to the Senate Health, Labor, and Pensions (HELP) Committee asking that benefit protections for mental health and substance use disorder treatment and recovery support services through the exchanges and individual/small group markets be maintained and that those benefits be offered consistent with the Mental Health Parity and Addiction Equity Act (MHPAEA as the committee works to develop a market stabilization framework.

Sep 14, 2018, 01:00 by admin admin

ASAM led a letter signed by 432 health organizations sharing concerns with the most recent version of the American Health Care Act (AHCA).

Sep 14, 2018, 01:00 by admin admin

Yesterday, President Trump’s Commission on Combating Drug Addiction and the Opioid Epidemic held its fifth and final meeting during which the commission approved its final report to the president.

Sep 14, 2018, 01:00 by admin admin

Today, the American Society of Addiction Medicine (ASAM) applauded U.S. Surgeon General Jerome M. Adams, MD, MPH, for encouraging more individuals, including family, friends, and those at risk for opioid overdose, to keep on hand naloxone, an FDA-approved medication that can reverse opioid-induced respiratory depression.

Sep 14, 2018, 01:00 by admin admin

ASAM and the Ohio Society of Addiction Medicine (OHSAM) sent a letter to the State of Ohio Board of Pharmacy and the Department of Mental Health and Addiction Services asking them to provide education and clarity to providers of office-based opioid treatment (OBOT) on new proposed rules.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted recommendations on the White House Opioid Commission’s Interim Report. The Interim Report outlines recommendations from the commission to inform the White House of the best methods to combat the opioid epidemic.

Sep 14, 2018, 01:00 by admin admin

ASAM and the New York Society of Addiction Medicine (NYSAM) submitted comments on emergency proposed regulations to align state law with federal law to allow NPs and PAs to prescribe buprenorphine for addiction treatment.

Sep 14, 2018, 01:00 by admin admin

ASAM joined 145 members of the Coalition to Stop Opioid Overdose and other organizations in sending a letter voicing support for the CARE Act of 2019. This legislation 2019 would provide $100 billion in federal funding over the next ten years to support federal research and programs to prevent drug use while expanding access to prevention, harm reduction, addiction treatment, mental health services, and recovery support services.

Sep 14, 2018, 01:00 by admin admin

ASAM and the Wisconsin Society of Addiction Medicine submitted a letter to the Wisconsin Department of Health Services (DHS), Division of Medicaid Services on its proposed amendments to provisions of its Section 1115 Demonstration Waiver (BadgerCare Reform Demonstration Waiver).

Sep 14, 2018, 01:00 by admin admin

ASAM and the New Jersey Society of Addiction Medicine (NJSAM) submitted letters of support with recommended revision for A4138 and S1051, legislation that would require state insurance providers to cover the costs of buprenorphine and prohibit utilization controls.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted comments on proposed revised regulations in Delaware to restrict opioid prescribing via telemedicine to only permit the prescribing of medications used to treat addiction, such as buprenorphine.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted comments regarding SAMHSA's Supplemental Notice of Proposed Rulemaking (SNPRM) on the Confidentiality of Substance Use Disorder Patient Records (42 CFR part 2).

Sep 14, 2018, 01:00 by admin admin

The American Society of Addiction Medicine (ASAM) and the American Medical Association (AMA) jointly announced today the release of a concept paper detailing a groundbreaking alternative payment model (APM) that could revolutionize how patients with opioid use disorder are treated.

Sep 14, 2018, 01:00 by admin admin

ASAM joined a coalition letter expressing support for the Bipartisan Health Care Stabilization Act of 2017 and leading bipartisan efforts to provide stabilization to the health insurance marketplace. 

Sep 14, 2018, 01:00 by admin admin

ASAM led a coalition letter signed by 465 organizations sharing serious concerns regarding the Better Care Reconciliation Act (BCRA). The letter emphasized how the BCRA’s proposed changes to the health care system will result in reductions in health care coverage, particularly for vulnerable populations including those suffering from substance use disorders and mental illness.

Sep 14, 2018, 01:00 by admin admin

ASAM and the New Jersey Society of Addiction Medicine (NJSAM) submitted letters of support with a recommended revision for A4910 and S3272, legislation that would align state law with federal law to allow NPs and PAs to prescribe buprenorphine for addiction treatment.

Sep 14, 2018, 01:00 by admin admin

On December 30, 2017, the Food and Drug Administration (FDA) announced the approval of Sublocade, a monthly formulation of buprenorphine subcutaneous injection for treatment of opioid dependence. This injection is the first monthly formulation of buprenorphine to be approved by the FDA.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted comment letters to the Food and Drug Administration (FDA) with recommendations regarding its proposed Blueprint for the extended-release, long-acting (ER/LA) Opioid Risk Evaluation and Mitigation Strategy (REMS) training as well as whether such training should be mandatory for all ER/LA opioid prescribers.

Sep 14, 2018, 01:00 by admin admin

ASAM signed onto a letter sent to the Senior Advisor to the President regarding the Office of Management and Budget's (OMB) proposed budget which would slash funding for the Office of National Drug Control Policy (ONDCP) and drug control program funding.